Fotiou Anastasios, Kanavou Eleftheria, Antaraki Argyro, Richardson Clive, Terzidou Manina, Kokkevi Anna
1Epidemiology Unit, Greek Reitox Focal Point of the EMCDDA, University Mental Health Research Institute, 2 Soranou tou Efesiou St., Athens, 11527 Greece.
2Panteion University of Social and Political Sciences, 136, Leoforos A. Siggrou, Kallithea, Athens 17671 Greece.
Hepatol Med Policy. 2016 Aug 25;1:9. doi: 10.1186/s41124-016-0017-5. eCollection 2016.
HCV/HIV coinfection in people who inject drugs is a public health issue, which presents a variety of challenges to healthcare providers. The determinants of HCV/HIV coinfection in this population are nonetheless not well known. The aim of the present study is to identify the factors associated with HCV/HIV coinfection in people who inject drugs and enter drug-related treatment.
Linked serological and behavioral data were collected from people who entered 38 opioid substitution treatment clinics in central and southern Greece between January and December 2013. Three mutually exclusive groups were defined based on the presence of HCV and HIV antibodies. Group 1 clients had neither infection, Group 2 had HCV but not HIV, and Group 3 had HCV/HIV coinfection. Multinomial logistic regression analyses identified differences between groups according to socio-demographic, drug use and higher-risk behavioral characteristics.
Our study population consisted of 580 people who injected drugs in the past 12 months (79.8 % males, with median age 36 years).79.4 % were HCV and 15.7 % HIV infected. Of those with complete serological data in both HCV and HIV indicators, 20.4 % were uninfected, 64.0 % HCV monoinfected, and 14.9 % HCV/HIV coinfected. HCV infection with or without HIV coinfection was positively associated with living alone or with a spouse/partner without children, prior incarceration, drug injecting histories of ≥10 years, and syringe sharing in the past 12 months, and negatively associated with never having previously been tested for HCV. HCV/HIV coinfection, but not HCV infection alone, was positively associated with residence in urban areas (relative risk ratio [RRR] = 4.8, 95 % confidence interval [CI]: 1.7-13.7, = 0.004) and averaging >3 injections a day in the past 30 days (RRR = 4.5, 95 % CI: 1.6-12.8, = 0.005), and negatively associated with using a condom in the last sexual intercourse.
People who inject drugs and live in urban areas and inject frequently have higher risk of coinfection. Findings highlight the need for scaling-up needle and syringe programs in inner city areas and promoting access of this population to screening and treatment, especially in prisons. The protective role of living with parents and children could inform the implementation of indicated interventions.
注射吸毒者中的丙型肝炎病毒(HCV)/艾滋病病毒(HIV)合并感染是一个公共卫生问题,给医疗服务提供者带来了各种挑战。然而,这一人群中HCV/HIV合并感染的决定因素尚不清楚。本研究的目的是确定与注射吸毒并接受药物相关治疗者的HCV/HIV合并感染相关的因素。
收集了2013年1月至12月期间进入希腊中部和南部38家阿片类药物替代治疗诊所的患者的血清学和行为数据。根据HCV和HIV抗体的存在情况定义了三个相互排斥的组。第1组患者既无感染,第2组有HCV但无HIV,第3组为HCV/HIV合并感染。多项逻辑回归分析根据社会人口统计学、药物使用和高风险行为特征确定了组间差异。
我们的研究人群包括580名在过去12个月内注射过毒品的人(79.8%为男性,中位年龄36岁)。79.4%感染了HCV,15.7%感染了HIV。在HCV和HIV指标均有完整血清学数据的患者中,20.4%未感染,64.0%为HCV单感染,14.9%为HCV/HIV合并感染。无论是否合并HIV感染,HCV感染均与独居或与无子女的配偶/伴侣生活、既往监禁、注射毒品史≥10年以及过去12个月内共用注射器呈正相关,与从未接受过HCV检测呈负相关。HCV/HIV合并感染而非单独的HCV感染与城市居住(相对风险比[RRR]=4.8,95%置信区间[CI]:1.7-13.7,P=0.004)以及过去30天内平均每天注射>3次(RRR=4.5,95%CI:1.6-12.8,P=0.005)呈正相关,与上次性交时使用避孕套呈负相关。
居住在城市地区且频繁注射毒品的人合并感染的风险更高。研究结果强调需要在市中心地区扩大针头和注射器项目,并促进这一人群获得筛查和治疗,尤其是在监狱中。与父母和子女共同生活的保护作用可为针对性干预措施的实施提供参考。